The vaccine developed by Johnson & Johnson has varying efficacies as shown by FDA documents. In the United States, efficiency is at 72%, 66% in Latin America, and about 64% in South Africa.
Besides the European Commission that just inked a deal with Moderna, the US ranks as one that has shown the highest commitment to both the vaccine development and its acquisition upon approval.
Pfizer is on track to deliver up to 50 million doses in 2020 and about 1.3 billion doses in 2021.
Gilead Sciences Inc revealed on Thursday that the Food and Drug Administration (FDA) has given the approval to Remdesivir as the first official treatment for COVID-19 in the United States.